 MaxCyte Inc AIM:MXCT has signed a strategic platform licence with a South Korean biotechnology company to enable cell and gene therapies for the treatment of rare intractable diseases. The cell engineering company said it will receive platform licensing fees and program-related revenue as part of the agreement. 